Parallax Volatility Advisers
RNTX

Parallax Volatility Advisers’s Rein Therapeutics RNTX Stock Holding History

Parallax Volatility Advisers’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-40
Closed -$8K – 4505
2017
Q4 		$8K Buy
+40
New +$9.59K ﹤0.01% 3814

Other funds holding RNTX

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallax Volatility Advisers's RNTX Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Rein Therapeutics (RNTX) in Q1 2018, closing a stake of 40 shares — an estimated $8K sold.

Parallax Volatility Advisers first reported a position in RNTX in Q4 2017 and held it in 1 quarter. The position peaked at $8K in Q4 2017. 27 funds tracked by Wall St. Rank hold RNTX as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining Rein Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 40 Rein Therapeutics shares in Q1 2018, an estimated $8K.
  • Parallax Volatility Advisers first reported a position in Rein Therapeutics in Q4 2017 and held it in 1 quarter.
  • Parallax Volatility Advisers's Rein Therapeutics position peaked at $8K in Q4 2017.
  • 27 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.